ReviewJournal of personalized medicine2021
Which Therapy for Non-Type(T)2/T2-Low Asthma.
Review in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Periostin in allergic rhinitis: from pathogenic mediator to predictive biomarker and therapeutic target.Frontiers in pharmacology · 2026Pooled it
- AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma.British journal of clinical pharmacology · 2026Trial
- Beyond the Usual Suspects: Unmasking Low-T2 Asthma in Children.Journal of clinical medicine · 2026Review
- Mechanistic insights into the therapeutic potential of β-elemene on glioma and other central nervous system diseases.Medical oncology (Northwood, London, England) · 2025Review
- Unmasking Pediatric Asthma: Epigenetic Fingerprints and Markers of Respiratory Infections.International journal of molecular sciences · 2025Review
- Advances in Biologic Therapies for Allergic Diseases: Current Trends, Emerging Agents, and Future Perspectives.Journal of clinical medicine · 2025Review
- The Circadian Rhythm of Asthma Immune Metabolism.Journal of immunology research · 2025Review
- Anti-aminoacyl-tRNA synthetase-interacting multifunctional protein-1 antibody improves airway inflammation in mice with house dust mite induced asthma.The World Allergy Organization journal · 2024Article
- Association of Small Airway Functional Indices With Respiratory Symptoms and Comorbidity in Asthmatics: A National Cross-Sectional Study.Journal of clinical medicine research · 2024Article
- New targets for type 2-low asthma.The Korean journal of internal medicine · 2024Review
- Efficacy of tezepelumab against uncontrolled severe non-type 2 asthma refractory to bronchial thermoplasty, benralizumab, dupilumab and mepolizumab.Respirology case reports · 2024Article
- Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies.Frontiers in immunology · 2024Review
- The Dual Role of the Airway Epithelium in Asthma: Active Barrier and Regulator of Inflammation.Cells · 2023Review
- Article
- Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity.Frontiers in pharmacology · 2023Review
- Paucigranulocytic Asthma: Potential Pathogenetic Mechanisms, Clinical Features and Therapeutic Management.Journal of personalized medicine · 2022Review
- Identifying key genes and functionally enriched pathways in Th2-high asthma by weighted gene co-expression network analysis.BMC medical genomics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, the asthmatic population is divided into Type 2-high and non-Type 2/Type 2-low asthmatics, with 50% of patients belonging to one of the two groups. Differently from T2-high, T2-low asthma has not been clearly defined yet, and the T2-low patients are identified on the basis of the absence or non-predominant expression of T2-high biomarkers. The information about the molecular mechanisms underpinning T2-low asthma is scarce, but researchers have recognized as T2-low endotypes type 1 and type 3 immune response, and remodeling events occurring without inflammatory processes. In addition, the lack of agreed biomarkers reprents a challenge for the research of an effective therapy. The first-choice medication is represented by inhaled corticosteroids despite a low efficacy is reported for/in T2-low patients. However, macrolides and long-acting anti-muscarinic drugs have been recognized as efficacious. In recent years, clinical trials targeting biomarkers playing key roles in T3 and T1 immune pathways, alarmins, and molecules involved in neutrophil recruitment have provided conflicting results probably misleading (or biased) in patients' selection. However, further studies are warranted to achieve a precise characterization of T2-low asthma with the aim of defining a tailored therapy for each single asthmatic patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.